Rationale for, barriers to, and appropriate medication for the long-term treatment of depression
- PMID: 20371029
- DOI: 10.4088/JCP.9058se1c.02gry
Rationale for, barriers to, and appropriate medication for the long-term treatment of depression
Abstract
Antidepressants have proven efficacy in the treatment of acute depressive episodes and the prevention of relapse over the long-term. However, whether due to ignorance about the chronicity of depression, intolerable adverse effects, or an inappropriate fear of dependence, antidepressants are often discontinued after remission or recovery from an acute episode, which frequently leads to relapse or recurrence. This, in turn, increases the risk of subsequent poor treatment response and lifelong depressive chronicity. Clinicians should focus on preventing depressive relapse with long-term antidepressant pharmacotherapy, thereby improving patients' overall outcomes, particularly with patients at high risk for relapse. When patients with depression have comorbid anxiety, benzodiazepines may be useful but should be used only as short-term augmentation during the beginning phase of antidepressant treatment; long-term treatment of comorbid anxiety is better managed by antidepressants that also treat anxiety disorders.
Similar articles
-
The effects of continuous antidepressant treatment during the first 6 months on relapse or recurrence of depression.J Affect Disord. 2011 Jul;132(1-2):121-9. doi: 10.1016/j.jad.2011.02.016. Epub 2011 Mar 12. J Affect Disord. 2011. PMID: 21402412
-
Enhancing the efficacy of antidepressants with psychotherapy.J Psychopharmacol. 2006 May;20(3 Suppl):19-28. doi: 10.1177/1359786806064314. J Psychopharmacol. 2006. PMID: 16644768 Review.
-
Update on partial response in depression.J Clin Psychiatry. 2009;70 Suppl 6:4-9. doi: 10.4088/JCP.8133su1c.01. J Clin Psychiatry. 2009. PMID: 19922738 Review.
-
Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.CNS Spectr. 2007 Aug;12(8 Suppl 13):1-27. CNS Spectr. 2007. PMID: 17986951 Review.
-
Long-term effectiveness of cognitive therapy in major depressive disorder.Depress Anxiety. 2004;20(1):1-7. doi: 10.1002/da.20022. Depress Anxiety. 2004. PMID: 15368590 Review.
Cited by
-
Multi-modality: a new approach for the treatment of major depressive disorder.Int J Neuropsychopharmacol. 2013 Jul;16(6):1433-1442. doi: 10.1017/S1461145712001605. Epub 2013 Jan 30. Int J Neuropsychopharmacol. 2013. PMID: 23363735 Free PMC article.
-
Ventral Hippocampal Input to Infralimbic Cortex Is Necessary for the Therapeutic-Like Effects of Extinction in Stressed Rats.Int J Neuropsychopharmacol. 2023 Aug 29;26(8):529-536. doi: 10.1093/ijnp/pyad043. Int J Neuropsychopharmacol. 2023. PMID: 37480574 Free PMC article.
-
The Impact of Treatments for Depression on the Dynamic Network Structure of Mental States: Two Randomized Controlled Trials.Sci Rep. 2017 Apr 20;7:46523. doi: 10.1038/srep46523. Sci Rep. 2017. PMID: 28425449 Free PMC article.
-
Adjunct treatment with ketamine enhances the therapeutic effects of extinction learning after chronic unpredictable stress.Neurobiol Stress. 2022 Jul 8;19:100468. doi: 10.1016/j.ynstr.2022.100468. eCollection 2022 Jul. Neurobiol Stress. 2022. PMID: 35865972 Free PMC article.
-
Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission.Neuropsychopharmacol Rep. 2022 Sep;42(3):306-314. doi: 10.1002/npr2.12269. Epub 2022 Jul 1. Neuropsychopharmacol Rep. 2022. PMID: 35775506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical